Seattle Genetics Inc. (NASDAQ:SGEN) shares traded up 2.4% during trading on Friday . The stock traded as high as $43.27 and last traded at $43.01, with a volume of 284,202 shares. The stock had previously closed at $42.01.

Several research analysts have recently commented on the stock. Cantor Fitzgerald restated a “buy” rating and set a $43.00 price target on shares of Seattle Genetics in a research note on Wednesday, June 8th. Credit Suisse Group AG reiterated a “buy” rating on shares of Seattle Genetics in a research note on Wednesday, June 8th. Zacks Investment Research upgraded shares of Seattle Genetics from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a research note on Monday, July 4th. HC Wainwright reiterated a “buy” rating and issued a $65.00 target price on shares of Seattle Genetics in a research note on Monday, June 13th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $72.00 target price (up from $60.00) on shares of Seattle Genetics in a research note on Wednesday, June 29th. One research analyst has rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $46.61.

The company has a 50-day moving average price of $40.53 and a 200-day moving average price of $36.48. The firm’s market capitalization is $6.02 billion.

Seattle Genetics (NASDAQ:SGEN) last announced its quarterly earnings data on Thursday, April 28th. The company reported ($0.15) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.09) by $0.06. The firm had revenue of $111.15 million for the quarter, compared to analyst estimates of $116.49 million. During the same quarter in the previous year, the company posted ($0.17) earnings per share. The firm’s quarterly revenue was up 35.3% compared to the same quarter last year. On average, analysts anticipate that Seattle Genetics Inc. will post ($1.10) earnings per share for the current fiscal year.

In other Seattle Genetics news, CEO Clay B. Siegall sold 800 shares of the company’s stock in a transaction on Monday, April 25th. The shares were sold at an average price of $40.00, for a total transaction of $32,000.00. Following the sale, the chief executive officer now directly owns 556,915 shares of the company’s stock, valued at $22,276,600. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Clay B. Siegall sold 22,083 shares of the company’s stock in a transaction on Monday, June 6th. The stock was sold at an average price of $43.59, for a total transaction of $962,597.97. Following the sale, the chief executive officer now directly owns 566,538 shares in the company, valued at $24,695,391.42. The disclosure for this sale can be found here.

Other hedge funds have recently bought and sold shares of the company. Eagle Asset Management raised its stake in Seattle Genetics by 53.2% in the third quarter. Eagle Asset Management now owns 594,490 shares of the company’s stock valued at $22,922,000 after buying an additional 206,317 shares during the period. New York State Common Retirement Fund raised its stake in Seattle Genetics by 12.7% in the fourth quarter. New York State Common Retirement Fund now owns 388,566 shares of the company’s stock valued at $17,439,000 after buying an additional 43,913 shares during the period. California Public Employees Retirement System raised its stake in Seattle Genetics by 14.0% in the fourth quarter. California Public Employees Retirement System now owns 294,700 shares of the company’s stock valued at $13,226,000 after buying an additional 36,300 shares during the period. Rhumbline Advisers raised its stake in Seattle Genetics by 7.7% in the fourth quarter. Rhumbline Advisers now owns 101,662 shares of the company’s stock valued at $4,563,000 after buying an additional 7,225 shares during the period. Finally, Whalerock Point Partners LLC raised its stake in Seattle Genetics by 47.7% in the fourth quarter. Whalerock Point Partners LLC now owns 38,550 shares of the company’s stock valued at $1,730,000 after buying an additional 12,450 shares during the period.

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company’s product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC), comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.